28 September 2016
The brilliant film portrayal by Meryl Streep of the tone-deaf diva Florence Foster Jenkins is amplified in the historian Darryl W. Bullock's fine new book, Florence ! Foster !! Jenkins !!! the Life of the World's Worst Opera Singer (Overlook Press, New York, 2016). I offer here a scientific postulation for this striking example of "dysmusia " (or tune-deafness), of which she was quite likely cognitively unaware.
25 September 2016
Recently, Miklossy has shown Borrelia cultured from brains of Alzheimer’s disease (AD) not only grew organisms, but those organisms made biofilms, amyloid-β protein precursor (AβPP), and amyloid-β (Aβ) in vitro as well . With that observation, the major events in the pathogenesis of this dreaded disease have been made much clearer. They (major events) originate in most cases of the disease with spirochetes; Aβ, which is a constant in the disease, assumes a lesser role.
6 September 2016
Diabetes has been known to affect Alzheimer’s disease (AD) adversely [1, 2]. A recent article postulated that the mechanism for this occurrence was comprised of four underlying malfunctions.
4 August 2016
We read with interest the article by Eichler et al.  that indicates that a high proportion of community-dwelling people with dementia live alone. The authors concluded that people with dementia living alone did not seem to be at an increased health risk, even if they lacked the support of an informal caregiver. We would like to comment on safety issues about living alone with dementia.
7 June 2016
The editorial paper by Itzhaki et al.  addresses critically important questions about the role of infection in etiology of Alzheimer's disease (AD). We believe that in addition to the evidence of infectious nature of AD that have been described in the paper, one more type of the evidence must be taken into account and routinely included in consideration of AD mechanisms.
26 December 2015
Inhalable curcumin is a potential treatment for herpes simplex virus type 1-associated Alzheimer’s disease
Herpes simplex virus type 1 (HSV-1) DNA is frequently detected in the aged brains of both normal individuals and patients with Alzheimer’s disease (AD) . In recent studies, the reactivation of HSV-1 in the brain is a potent risk factor for the development of AD . Reactivated HSV-1 can cause an increased formation and accumulation of amyloid-β (Aβ) and abnormally phosphorylated tau. Moreover, HSV-1-mediated disruption of autophagy in neurons may also contribute to the accumulation of these abnormal proteins .
21 September 2015
Further verification of the lack of correlation between Lyme disease and deaths due to Alzheimer’s disease
In 2014, O’Day and Catalano published a JAD article presenting statistical evidence that Lyme disease was not a cause of Alzheimer’s disease . A recent report by Phillip J. Baker, Ph.D., who is the Executive Director of the American Lyme Disease Foundation, has validated this conclusion using different statistical methodology and more recent data . To quote Dr. Baker, “An analysis of the data by linear regression analysis generates a correlation coefficient of 0.0753 (t= 0.262 for 12 degrees of freedom; p >0.05.
31 July 2015
Two compartment model of MSH/ACTH may be a surrogate for intranasal insulin central nervous system kinetics
4 June 2015
Insulin signaling is impaired in Alzheimer’s disease . In the SNIFF Trial, Claxton et al. have reported that long-acting intranasal insulin Detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease . Adverse effects included mild rhinitis. In an earlier publication, Craft et al. note 8.3% nosebleeds and 16.7% rhinitis with a 20 IU intranasal insulin dose .
19 March 2015
In their updated systematic review and meta-analysis, Wang and colleagues  identified 12 cohort studies, 5 case-control studies, and 1 randomized clinical trial (RCT). Based on an aggregate measure emanating from adjusted risk and hazard ratios, they reported that, within a meaningful degree of heterogeneity, non-steroidal anti-inflammatory drugs (NSAIDs) are statistically significantly associated with a 28% reduced risk of Alzheimer’s disease (AD) in the general population.